Srinivasu Poondru

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

Alfredo Berruti, Éric Baudin, Michael J. Demeure et al. · The Lancet Oncology · 2015 · 333 citations · Full text

Medicine, Oncology, Pharmacology +14

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

Ronan J. Kelly, Anish Thomas, Arun Rajan et al. · Annals of Oncology · 2013 · 172 citations · Full text

Medicine, Oncology, Pharmacology +17

Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control

Alex M. Aronov, Qing Tang, Gabriel Martínez-Botella et al. · Journal of Medicinal Chemistry · 2009 · 145 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +17

A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors

Igor Puzanov, Colin R. Lindsay, Laura W. Goff et al. · Clinical Cancer Research · 2014 · 99 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +16

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Robin L. Jones, Edward S. Kim, Pilar Nava-Parada et al. · Clinical Cancer Research · 2014 · 93 citations

Medicine, Oncology, Pharmacology +15